两组治疗耐药慢性乙肝方案的最小成本分析  

Cost-minimization analyses on the medication of lamivudine-resistant chronic hepatitis B

作　　者：周艳梅[1] 范广俊[2] 黄俊梓[2] 牟丽[2] 代琳娜[3] 

机构地区：[1]简阳市人民医院药剂科,四川简阳641400 [2]大连医科大学附属第二医院药剂科,辽宁大连116027 [3]大连医科大学药学院,辽宁大连116044

出　　处：《大连医科大学学报》2011年第5期489-491,共3页Journal of Dalian Medical University

摘　　要：[目的]比较两组治疗拉米夫定耐药的慢性乙型肝炎的方案的有效性及经济性。[方法]选择门诊拉米夫定耐药的慢性乙型肝炎患者150例,A组75例,给予恩替卡韦(ETV)0.5 mg,口服1次/d;B组75例,给予阿德福韦酯(ADV)10 mg及拉米夫定(LAM)100 mg,口服1次/d。观察两组治疗效果,并采用最小成本法分析。[结果]在HBV-DNA转阴率和ALT复常率等效果方面,两组差异无显著性意义(P>0.05),A组成本为13101元;B组成本为12382元。[结论]即时疗效分析两组相似,但从最小成本分析角度上看阿德福韦酯联合拉米夫定优于单用恩替卡韦方案。[ Objective] To study the validity and affordability between two ways in the treatment of lamivudine -resistant chronic hepatitis B. [ Methods ] One hundred and fifty patients with lamivudine -resistant chronic hepatitis B selected from clinic service were divided into group A and group B. Seventy - five patients in group A were treated with oral entecavir 0.5 mg/d, and 75 patients in group B were treated with oral adefovir dipivoxil 10 mg/d and lamivudine 100 mg/d. The therapeutic efficacy was monitored and the cost - minimization analyses were performed. [ Results ] There was no significant difference in the HBV - DNA negative rates and the ALT normalization rates between the two groups （ P 〉 0.05 ）. The treatment cost was 13,10l Yuan in group A and 12,382 Yuan in group B. [ Conclusion] The combination of ADV with LAM is better than ETV used alone in cost - effectiveness ratio in the treatment of lamivudine - resistant chronic hepatitis B.

关 键 词：耐拉米夫定的慢性乙型肝炎 恩替卡韦 阿德福韦酯 最小成本分析 

分 类 号：R512.62[医药卫生—内科学]